T1	condition 14 47	palmar-plantar erythrodysesthesia
T2	intervention 56 70	antiperspirant
T3	eligibility 74 141	breast cancer patients treated with pegylated liposomal doxorubicin
T4	control 520 533	placebo cream
T5	outcome-Measure 668 722	rate of grade 2 or 3 palmar-plantar erythrodysesthesia
T6	outcome-Measure 753 829	patient-reported symptom burden (tingling, numbness, pain, or skin problems)
T7	total-participants 869 871	53
T8	outcome 1010 1026	Grade 2 or 3 PPE
T9	total-participants 1051 1053	52
T10	cv-bin-abs 1077 1080	six
T11	outcome 1090 1105	adverse effects
T12	iv-bin-abs 1174 1177	one
T13	outcome 1196 1229	palmar-plantar erythrodysesthesia
T14	outcome 1293 1353	grade 2 or 3 palmar-plantar erythrodysesthesia on their foot
T15	cv-bin-abs 1269 1273	Four
